Microsoft launches Discovery platform that uses agentic AI to compress years of scientific research into days, transforming R&D across pharmaceuticals, materials science, and semiconductor industries.

Patients were randomised 1:1 to receive Nucala 100mg or placebo subcutaneously every four weeks in addition to standard ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

Microsoft Corp. today announced the launch of Microsoft Discovery, a new enterprise-grade artificial intelligence platform ...

A low-carbon version of a triple combination pMDI inhaler indicated for adults with moderate-to-severe COPD has been approved by the MHRA.

Eleven-year follow-up data continue to show the invasive disease-free survival benefit for node-positive patients seen in previous analyses.

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

The clinical trial for the potential vaccine, VLA15, began in August 2022. Stage 3 trials got underway in late 2023, ...

Investing.com -- GSK plc (LON: GSK ), a U.K.-based pharmaceutical company, said on Monday that its Blenrep combinations have been approved by Japan’s Ministry of Health. This approval is for the ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.